Tenure-Track Researcher
IT | EN
The result matters. The assumptions that produce it often matter more.
I work on health economics, Health Technology Assessment and policies governing access to health innovation.
I study how data, methods and evidence can support more transparent decisions on value, pricing, reimbursement and access. I am not only interested in estimating costs and outcomes: I aim to make the assumptions and decision pathways behind an assessment visible.
The questions I work on
Keywords help algorithms. Questions help research.
How do we measure the value of a health innovation?
I study how clinical outcomes, costs, quality of life and organisational impact can be integrated into an assessment that is useful for decision-making.
How do assessments change as new data become available?
I work on evidence updates, real-world data and the reassessment of technologies across their life cycle.
Which evidence should inform pricing, reimbursement and access?
I analyse the relationship between available evidence, uncertainty, comparators and decision-making processes in pharmaceutical policy.
How do we distinguish higher spending, broader access and loss of value?
I try to separate phenomena that are often conflated by reconstructing denominators, populations, observation periods and consequences for the Italian National Health Service.
How I work
An economic evaluation is not just a numerical result. It depends on the question being asked, the evidence available and the assumptions used to connect that evidence to decisions.
1
Define the question
Clarify which decision needs to be supported, for which population and against which alternatives.
2
Make assumptions visible
Explicitly state comparators, perspective, time horizon, data sources and the main sources of uncertainty.
3
Interpret the consequences
Translate findings into implications that are understandable and useful for patients, professionals, decision-makers and the Italian National Health Service.
Models produce numbers. Decisions, unfortunately, do not make themselves.
HETA LAB
Research is rarely an individual endeavour. Fortunately.
HETA Lab is dDRUG’s laboratory dedicated to health economics and Health Technology Assessment. It brings together economic, statistical, regulatory and clinical expertise to study the value of innovation, system sustainability and equity in access to care.
The Lab develops economic evaluations, predictive models and real-world analyses; studies pricing, reimbursement and access pathways; and promotes research and training for students, researchers and professionals.
Scientific profile
Andrea Marcellusi is a tenure-track researcher at the Department of Pharmaceutical Sciences, University of Milan. His research focuses on health economics, Health Technology Assessment, pharmacoeconomics, access to medicines, simulation modelling and the use of real-world evidence.
His work integrates economic evaluations, statistical and simulation models, real-world evidence and pharmaceutical policy analysis, with particular attention to methodological transparency and implications for the Italian National Health Service.